MetLife Investment Management LLC Has $3.60 Million Position in Revvity, Inc. (NYSE:RVTY)

MetLife Investment Management LLC increased its position in Revvity, Inc. (NYSE:RVTY) by 0.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 32,231 shares of the company’s stock after acquiring an additional 169 shares during the quarter. MetLife Investment Management LLC’s holdings in Revvity were worth $3,597,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Tidal Investments LLC increased its position in Revvity by 2,388.8% in the 3rd quarter. Tidal Investments LLC now owns 52,787 shares of the company’s stock valued at $6,744,000 after acquiring an additional 50,666 shares during the period. Principal Financial Group Inc. increased its holdings in Revvity by 3.1% in the third quarter. Principal Financial Group Inc. now owns 141,871 shares of the company’s stock valued at $18,124,000 after purchasing an additional 4,263 shares during the period. JPMorgan Chase & Co. raised its position in Revvity by 13.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 344,115 shares of the company’s stock worth $43,961,000 after purchasing an additional 41,497 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Revvity by 10.8% during the 4th quarter. GAMMA Investing LLC now owns 1,898 shares of the company’s stock worth $212,000 after buying an additional 185 shares during the period. Finally, Nordea Investment Management AB grew its position in shares of Revvity by 8.0% in the 4th quarter. Nordea Investment Management AB now owns 9,681 shares of the company’s stock valued at $1,084,000 after buying an additional 719 shares during the last quarter. Institutional investors and hedge funds own 86.65% of the company’s stock.

Revvity Stock Down 0.9 %

RVTY stock opened at $94.30 on Friday. The stock’s 50 day simple moving average is $104.87 and its 200 day simple moving average is $113.09. The company has a market cap of $11.33 billion, a P/E ratio of 42.67, a price-to-earnings-growth ratio of 3.82 and a beta of 1.07. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60. Revvity, Inc. has a fifty-two week low of $88.53 and a fifty-two week high of $129.50.

Revvity (NYSE:RVTY) last issued its earnings results on Friday, January 31st. The company reported $1.42 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same quarter last year, the business earned $1.25 EPS. On average, research analysts expect that Revvity, Inc. will post 4.94 earnings per share for the current fiscal year.

Revvity Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 8th. Stockholders of record on Friday, July 18th will be issued a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.30%. The ex-dividend date is Friday, July 18th. Revvity’s dividend payout ratio is currently 12.67%.

Insider Transactions at Revvity

In other Revvity news, insider Joel S. Goldberg sold 15,170 shares of the firm’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the transaction, the insider now directly owns 33,400 shares in the company, valued at approximately $4,232,782. This trade represents a 31.23 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.68% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

RVTY has been the topic of a number of recent analyst reports. Robert W. Baird cut their price objective on Revvity from $141.00 to $127.00 and set an “outperform” rating on the stock in a research note on Monday, April 21st. Raymond James restated an “outperform” rating and issued a $145.00 price target (up previously from $140.00) on shares of Revvity in a research report on Monday, February 3rd. Wells Fargo & Company decreased their price objective on shares of Revvity from $130.00 to $102.00 and set an “equal weight” rating for the company in a research report on Thursday, April 17th. KeyCorp boosted their target price on shares of Revvity from $132.00 to $145.00 and gave the company an “overweight” rating in a report on Monday, February 3rd. Finally, Barclays decreased their price target on Revvity from $140.00 to $110.00 and set an “overweight” rating for the company in a report on Thursday, April 10th. Four investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Revvity presently has an average rating of “Moderate Buy” and a consensus target price of $130.50.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.